Published in Eur J Haematol on April 01, 2005
The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia (2009) 1.30
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol (2009) 1.00
Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol (2007) 0.97
New drugs in multiple myeloma - role of carfilzomib and pomalidomide. Contemp Oncol (Pozn) (2014) 0.82
Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf (2012) 0.80
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol (2012) 0.76
Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol (2012) 0.75
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med (2006) 8.16
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet (2005) 4.36
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care (2013) 3.65
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood (2008) 3.22
Management of bleeding following major trauma: an updated European guideline. Crit Care (2010) 3.09
Inter-rater reliability of nursing home quality indicators in the U.S. BMC Health Serv Res (2003) 2.83
Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol (2003) 2.77
Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology (2012) 2.64
A continuous-wave Raman silicon laser. Nature (2005) 2.53
Characterization of complicated carotid plaque with magnetic resonance direct thrombus imaging in patients with cerebral ischemia. Circulation (2003) 2.43
Management of bleeding following major trauma: a European guideline. Crit Care (2007) 2.40
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol (2012) 2.33
Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol (2010) 2.32
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood (2011) 2.32
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood (2004) 2.31
Plasma D-dimers in the diagnosis of venous thromboembolism. Arch Intern Med (2002) 2.27
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol (2012) 2.25
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol (2012) 2.17
A high-speed silicon optical modulator based on a metal-oxide-semiconductor capacitor. Nature (2004) 2.17
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc (2005) 2.00
A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum (2007) 1.82
Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain (2003) 1.82
The ACTIVE cognitive training trial and health-related quality of life: protection that lasts for 5 years. J Gerontol A Biol Sci Med Sci (2006) 1.79
Clinical guidelines for testing for heritable thrombophilia. Br J Haematol (2010) 1.79
Home care quality indicators (HCQIs) based on the MDS-HC. Gerontologist (2004) 1.75
The effects of the ACTIVE cognitive training trial on clinically relevant declines in health-related quality of life. J Gerontol B Psychol Sci Soc Sci (2006) 1.69
The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol (2009) 1.67
The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol (2007) 1.60
Serum polybrominated diphenyl ether (PBDE) levels are higher in children (2-5 years of age) than in infants and adults. Environ Health Perspect (2009) 1.60
Prevalence of complicated carotid atheroma as detected by magnetic resonance direct thrombus imaging in patients with suspected carotid artery stenosis and previous acute cerebral ischemia. Circulation (2003) 1.58
A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol (2002) 1.57
Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain (2003) 1.55
Renal diffusion and BOLD MRI in experimental diabetic nephropathy. Blood oxygen level-dependent. J Magn Reson Imaging (2003) 1.54
Using a new taxonomy to combine the uncombinable: integrating results across diverse interventions. Psychol Aging (2003) 1.53
An all-silicon Raman laser. Nature (2005) 1.53
Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev (2010) 1.48
Comparison of ultrasound and magnetic resonance urography for evaluation of contralateral kidney in patients with multicystic dysplastic kidney disease. J Urol (2011) 1.44
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc (2004) 1.43
N2010 adult-onset Still's disease complicated by hemophagocytic syndrome and catastrophic antiphospholipid syndrome resulting in four limb amputation. Isr Med Assoc J (2013) 1.43
Genetic regulation of birth weight and fasting glucose by a common polymorphism in the islet cell promoter of the glucokinase gene. Diabetes (2005) 1.38
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut (2013) 1.37
Recoverable cognitive dysfunction at hospital admission in older persons during acute illness. J Gen Intern Med (2006) 1.35
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood (2009) 1.32
Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. J Immunol (2004) 1.30
Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol (2008) 1.28
Inn1 couples contraction of the actomyosin ring to membrane ingression during cytokinesis in budding yeast. Nat Cell Biol (2008) 1.21
Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices of oxidative stress and placental function. Am J Obstet Gynecol (2002) 1.20
Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer (2006) 1.18
Quantification of hemoglobin A2 by tandem mass spectrometry. Clin Chem (2007) 1.16
Key issues in advanced bleeding care in trauma. Shock (2006) 1.15
Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med (2002) 1.15
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage (2009) 1.15
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res (2010) 1.15
Electrically pumped hybrid AlGaInAs-silicon evanescent laser. Opt Express (2006) 1.15
Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med (2002) 1.10
An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells. Stem Cells (2011) 1.09
Isolated soy protein consumption reduces urinary albumin excretion and improves the serum lipid profile in men with type 2 diabetes mellitus and nephropathy. J Nutr (2004) 1.09
The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol (2011) 1.08
The differential diagnosis of splachnic vein thrombosis. Br J Haematol (2014) 1.07
Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ (2012) 1.07
Life-threatening motor neurotoxicity in association with bortezomib. Haematologica (2006) 1.07
The desperate need for good-quality clinical trials to evaluate the optimal source and dose of fibrinogen in managing bleeding. Crit Care (2011) 1.06
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. Eur J Health Econ (2012) 1.05
Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol (2007) 1.05
Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int (2008) 1.04
Tranexamic acid: less bleeding and less thrombosis? Crit Care (2012) 1.04
New directions in the diagnosis and treatment of pulmonary embolism in pregnancy. Am J Obstet Gynecol (2012) 1.03
Individual characteristics associated with PBDE levels in U.S. human milk samples. Environ Health Perspect (2010) 1.03
A genomic and proteomic investigation of the impact of preimplantation factor on human decidual cells. Am J Obstet Gynecol (2010) 1.03
Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J Clin Endocrinol Metab (2004) 1.02
The effects of body mass index on cerebral blood flow velocity. Clin Auton Res (2008) 1.01
Magnetic resonance direct thrombus imaging: a novel technique for imaging venous thromboemboli. Thromb Haemost (2003) 1.01
Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol (2004) 0.99
The inclusion of a business management module within the master of pharmacy degree: a route to asset enrichment? Pharm Pract (Granada) (2013) 0.99
The management of recurrent VTE in cancer patients receiving therapeutic anticoagulation: the use of dual anticoagulant therapy combined with an IVC filter. Blood Coagul Fibrinolysis (2010) 0.97
Effective quality improvement of thromboprophylaxis in acute medicine. BMJ Qual Saf (2011) 0.96
The Indiana Alzheimer Disease Center's Symposium on Mild Cognitive Impairment. Cognitive training in older adults: lessons from the ACTIVE Study. Curr Alzheimer Res (2009) 0.95
Why carry out a longitudinal birth survey? Paediatr Perinat Epidemiol (2009) 0.94
Rapid and specific detection of clinically significant haemoglobinopathies using electrospray mass spectrometry-mass spectrometry. Br J Haematol (2005) 0.94
A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Invest (2012) 0.94
Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2004) 0.93
The role of dietary vitamin K in the management of oral vitamin K antagonists. Blood Rev (2011) 0.92
Mild traumatic brain injury and fatigue: a prospective longitudinal study. Brain Inj (2010) 0.92
Anticonvulsant hypersensitivity syndrome: treatment with corticosteroids and intravenous immunoglobulin. South Med J (2004) 0.92
Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. J Rheumatol (2011) 0.92
The management of perioperative bleeding. Blood Rev (2003) 0.91
Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res (2005) 0.91
First thalidomide clinical trial in multiple myeloma: a decade. Blood (2008) 0.90
Investigational methods for peroxisomal disorders. Curr Protoc Hum Genet (2008) 0.90
Cross-linking of cellular proteins by tissue transglutaminase during necrotic cell death: a mechanism for maintaining tissue integrity. Biochem J (2003) 0.90
The relationship among thromboelastography, hemostatic variables, and bleeding after cardiopulmonary bypass surgery in children. Anesth Analg (2010) 0.90
Transient activation of meox1 is an early component of the gene regulatory network downstream of hoxa2. Mol Cell Biol (2011) 0.90
Unprovoked venous thromboembolism: assess for cancer. Lancet Oncol (2012) 0.89